Apparent beneficial effects of tamoxifen on bone mineral content in patients with breast cancer: preliminary study.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 1790419.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Eight postmenopausal women undergoing adjuvant treatment with tamoxifen (20 mg/day) for breast cancer had baseline pretreatment, and 6- and 12-month post-treatment dual-photon determinations of vertebral bone mineral content (BMC). BMC measured at 6 and 12 months increased over baseline in all subjects. These observations imply that women treated with tamoxifen may retain rather than surrender the protective effect of estrogen against osteoporosis.
Medical subject headings
- Bone Density
- Breast Neoplasms
- Tamoxifen